Theratechnologies Inc. (TH.TO)
| Previous close | 1.8500 |
| Open | 1.8800 |
| Bid | 1.8800 x 0 |
| Ask | 1.9000 x 0 |
| Day's range | 1.8300 - 1.8900 |
| 52-week range | 1.2200 - 5.8400 |
| Volume | |
| Avg. volume | 29,116 |
| Market cap | 86.902M |
| Beta (5Y monthly) | 1.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2500 |
| Earnings date | 10 Jul 2024 - 15 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.42 |
ZacksTheratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?
Theratechnologies (THTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GlobeNewswireTheratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has mailed its 2024 management proxy circular to shareholders in connection with its virtual annual meeting of shareholders to be held on May 9, 2024, at 10:00 a.m. ET. Shareholders are encouraged to vote their shares for the propos
- GlobeNewswire
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
MONTREAL, April 11, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company’s President and CEO, Paul Lévesque will be presenting at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is taking place April 16-17 in Toronto, Canada. Presentation Details: Date/Time:Wednesday, April 17, 2024, at
